Daiichi Sankyo Co. Ltd. Ads (DSNKY) 19.9900 $DSNKY
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"
, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates.
PIRS: 2.65 (+0.14)
Cardiac Fibrosis - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw9tch/cardiac_fibrosis) has announced the addition of the "Cardiac Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AstraZeneca PLC - BioLineRx, Ltd. - Daiichi Sankyo Company, Limited - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/xw...c_fibrosis
AZN: 66.45 (+1.90), GALT: 2.67 (+0.12)
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
PR Newswire - Thu Jun 18, 7:00AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational study, which will investigate the efficacy and safety of edoxaban, marketed in the U.S. as SAVAYSA®, an oral, once-daily selective factor Xa inhibitor, versus dalteparin for the treatment of VTE associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term treatment with a low molecular weight heparin (LMWH) is intended.1 The purpose of the study is to evaluate edoxaban in comparison with dalteparin in preventing the combined outcome of VTE recurrence or major bleeding following an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) event in patients with cancer. The recruitment has started, and approximately 1,000 patients are expected to be enrolled in the study at clinical sites across 13 countries.1
Tetanus Pipeline Review, H1 2015 - 15 Companies & 21 Drug Profiles
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpr2j6/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Bharat Biotech International Limited - Biological E. Limited - Daiichi Sankyo Company, Limited - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Zydus Cadila Healthcare Limited Drug Profiles - (diphtheria tetanus pertussis (acelluar) poliovirus (types 1, 2 ,3)) vaccine - (diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis haemophilus influenza [serogroup B]) vaccine - diphtheria pertussis tetanus hepatitis [serotype B] haemophilus influenza [serotype B] vaccine - diphtheria pertussis tetanus vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria tetanus pertussis (whole cell) haemophilus influenzae [type B] polio (pentavalent) vaccine - diphtheria tetanus pertussis (whole cell) hepatitis B haemophilus influenzae [type B] polio (hexavalent) vaccine - diphtheria tetanus pertussis (whole-cell) haemophilus influenzae [serotype B] vaccine - diphtheria tetanus pertussis (whole-cell) hepatitis B haemophilus influenzae [serotype B] (pentavalent) vaccine - diphtheria tetanus pertussis (whole-cell) hepatitis B haemophilus influenzae [serotype B] vaccine - diphtheria tetanus pertussis (whole-cell) poliomyelitis haemophilus influenzae [serotype B] hepatitis B meningococcal [serotype C] (7-valent) vaccine - diphtheria tetanus pertussis (whole cell) vaccine - diphtheria tetanus pertussis (wholecell) hepatitis [Type B] haemophilus influenzae [type B] (pentavalent) vaccine - diphtheria tetanus pertussis (wholecell) hepatitis [Type B] poliomyelitis haemophilus influenzae [type B] (hexavalent) vaccine - diphtheria tetanus pertussis (whole-cell) vaccine - diphtheria tetanus vaccine - DTaP Vaccine - GC-1107 - GC-3111A - tetanus diphtheria pertussis (acellular) vaccine - VN-0103 For more information visit http://www.researchandmarkets.com/research/dpr2j6/tetanus
SVA: 5.26 (+0.02), NVS: 103.22 (+3.20)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 66.45 (+1.90)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 7.25 (unch), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GLPG: 53.06 (+0.56), IDRA: 3.49 (+0.05), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), RTRX: 33.59 (+1.88), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06), XLRN: 30.03 (+0.20)
Global Venous Thromboembolism Therapeutics Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3cbpk/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - edoxaban tosylate - Gammarin - GCC-2107 - GMI-1271 - ISIS-FXIRx - Lysimab - REG-2 - rivaroxaban - semuloparin For more information visit http://www.researchandmarkets.com/research/z3cbpk/venous
PTLA: 46.44 (+1.05), ISIS: 53.50 (+0.42), GLYC: 7.62 (+0.30), RGDO: 1.21 (unch)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 23.42 (+0.45), CTIC: 1.91 (+0.03), ABBV: 69.23 (+1.26), EXEL: 3.68 (+0.25), MGNX: 38.85 (+3.03), INCY: 108.33 (+0.22), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ATNM: 2.41 (+0.18), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), CALA: 6.77 (unch), AVEO: 1.57 (unch), AGIO: 109.82 (+2.33), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 5.64 (+0.25), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CTIC: 1.91 (+0.03), CNCE: 15.71 (+0.27), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), CCXI: 8.60 (+0.19), ICPT: 247.71 (+4.45), ABBV: 69.23 (+1.26)
Liposarcoma Pipeline Review 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sccfph/liposarcoma) has announced the addition of the "Liposarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Daiichi Sankyo Company, Limited - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Sanofi Drug Profiles - cabazitaxel - efatutazone - everolimus - palbociclib - pembrolizumab - ribociclib - SAR-405838 - selinexor - trabectedin - Liposarcoma For more information visit http://www.researchandmarkets.com/research/sc...iposarcoma
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 388.23 (-11.06), ACOR: 34.07 (+0.65), GSK: 42.45 (+0.65), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.58 (-0.02), GALE: 1.63 (+0.10), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)
Idiopathic (Essential) Hypertension Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ftwwp9/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - Jiangsu Hengrui Medicine Co., Ltd. - Lee's Pharmaceutical Holdings Limited - PhaseBio Pharmaceuticals, Inc. - Quantum Genomics SA - Takeda Pharmaceutical Company Limited Drug Profiles - (amlodipine besylate azilsartan medoxomil hydrochlorothiazide) - (amlodipine besylate candesartan) - (nifedipine candesartan cilexetil) - azilsartan medoxomil - carvedilol phosphate ER - - carvedilol SR - CS-3150 - LY-2623091 - PB-1120 - QGC-001 - rostafuroxin For more information visit http://www.researchandmarkets.com/research/ftwwp9/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 88.29 (+0.81)
Pulmonary Embolism Pipeline Review 2015 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Mon Apr 27, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f85q3d/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - F. Hoffmann-La Roche Ltd. Drug Profiles - apixaban - edoxaban tosylate - rivaroxaban - Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - SMTP-7 - TRX-1 For more information visit http://www.researchandmarkets.com/research/f85q3d/pulmonary
BMY: 69.27 (+1.38)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 1.94 (-0.19), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CBPO: 111.03 (+7.77), DERM: 18.22 (+0.30), CCXI: 8.60 (+0.19), ANAC: 84.61 (+1.95), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14)
Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
PR Newswire Europe - Fri Apr 24, 6:56AM CDT
TOKYO, April 24, 2015 /PRNewswire/ --
Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 2:30PM CDT
The report "Pulmonary Embolism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-em...eport.html .
BMY: 69.27 (+1.38)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"
, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates. PIRS: 2.65 (+0.14)
Cardiac Fibrosis - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw9tch/cardiac_fibrosis) has announced the addition of the "Cardiac Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AstraZeneca PLC - BioLineRx, Ltd. - Daiichi Sankyo Company, Limited - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/xw...c_fibrosis
AZN: 66.45 (+1.90), GALT: 2.67 (+0.12)
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
PR Newswire - Thu Jun 18, 7:00AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational study, which will investigate the efficacy and safety of edoxaban, marketed in the U.S. as SAVAYSA®, an oral, once-daily selective factor Xa inhibitor, versus dalteparin for the treatment of VTE associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term treatment with a low molecular weight heparin (LMWH) is intended.1 The purpose of the study is to evaluate edoxaban in comparison with dalteparin in preventing the combined outcome of VTE recurrence or major bleeding following an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) event in patients with cancer. The recruitment has started, and approximately 1,000 patients are expected to be enrolled in the study at clinical sites across 13 countries.1
Tetanus Pipeline Review, H1 2015 - 15 Companies & 21 Drug Profiles
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpr2j6/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Bharat Biotech International Limited - Biological E. Limited - Daiichi Sankyo Company, Limited - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Zydus Cadila Healthcare Limited Drug Profiles - (diphtheria tetanus pertussis (acelluar) poliovirus (types 1, 2 ,3)) vaccine - (diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis haemophilus influenza [serogroup B]) vaccine - diphtheria pertussis tetanus hepatitis [serotype B] haemophilus influenza [serotype B] vaccine - diphtheria pertussis tetanus vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria tetanus pertussis (whole cell) haemophilus influenzae [type B] polio (pentavalent) vaccine - diphtheria tetanus pertussis (whole cell) hepatitis B haemophilus influenzae [type B] polio (hexavalent) vaccine - diphtheria tetanus pertussis (whole-cell) haemophilus influenzae [serotype B] vaccine - diphtheria tetanus pertussis (whole-cell) hepatitis B haemophilus influenzae [serotype B] (pentavalent) vaccine - diphtheria tetanus pertussis (whole-cell) hepatitis B haemophilus influenzae [serotype B] vaccine - diphtheria tetanus pertussis (whole-cell) poliomyelitis haemophilus influenzae [serotype B] hepatitis B meningococcal [serotype C] (7-valent) vaccine - diphtheria tetanus pertussis (whole cell) vaccine - diphtheria tetanus pertussis (wholecell) hepatitis [Type B] haemophilus influenzae [type B] (pentavalent) vaccine - diphtheria tetanus pertussis (wholecell) hepatitis [Type B] poliomyelitis haemophilus influenzae [type B] (hexavalent) vaccine - diphtheria tetanus pertussis (whole-cell) vaccine - diphtheria tetanus vaccine - DTaP Vaccine - GC-1107 - GC-3111A - tetanus diphtheria pertussis (acellular) vaccine - VN-0103 For more information visit http://www.researchandmarkets.com/research/dpr2j6/tetanus
SVA: 5.26 (+0.02), NVS: 103.22 (+3.20)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 66.45 (+1.90)
Global Duchenne Muscular Dystrophy Therapeutics Pipeline Review, H1 2015
M2 - Mon Jun 08, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ppgk5r/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Asklepios BioPharmaceutical, Inc. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - EryDel SPA - Fate Therapeutics, Inc. - Galapagos NV - Genethon - Idera Pharmaceuticals, Inc. - Italfarmaco S.p.A. - Marathon Pharmaceuticals, LLC - Marina Biotech, Inc. - miRagen Therapeutics, Inc. - NicOx S.A. - Nippon Shinyaku Co., Ltd. - nLife Therapeutics, S.L. - Nobelpharma Co., Ltd. - Pfizer Inc. - Prosensa Therapeutics B.V. - Prothelia, Inc. - PTC Therapeutics, Inc. - Reata Pharmaceuticals, Inc. - Retrophin Inc. - ReveraGen BioPharma, Inc. - Sanofi - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Summit Corporation plc - Taiho Pharmaceutical Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/pp...e_muscular
FATE: 7.25 (unch), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GLPG: 53.06 (+0.56), IDRA: 3.49 (+0.05), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), RTRX: 33.59 (+1.88), PTCT: 46.49 (+1.75), SMMT: 11.27 (+0.06), XLRN: 30.03 (+0.20)
Global Venous Thromboembolism Therapeutics Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3cbpk/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - edoxaban tosylate - Gammarin - GCC-2107 - GMI-1271 - ISIS-FXIRx - Lysimab - REG-2 - rivaroxaban - semuloparin For more information visit http://www.researchandmarkets.com/research/z3cbpk/venous
PTLA: 46.44 (+1.05), ISIS: 53.50 (+0.42), GLYC: 7.62 (+0.30), RGDO: 1.21 (unch)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 23.42 (+0.45), CTIC: 1.91 (+0.03), ABBV: 69.23 (+1.26), EXEL: 3.68 (+0.25), MGNX: 38.85 (+3.03), INCY: 108.33 (+0.22), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ATNM: 2.41 (+0.18), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), CALA: 6.77 (unch), AVEO: 1.57 (unch), AGIO: 109.82 (+2.33), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 5.64 (+0.25), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CTIC: 1.91 (+0.03), CNCE: 15.71 (+0.27), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), CCXI: 8.60 (+0.19), ICPT: 247.71 (+4.45), ABBV: 69.23 (+1.26)
Liposarcoma Pipeline Review 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sccfph/liposarcoma) has announced the addition of the "Liposarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liposarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Daiichi Sankyo Company, Limited - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Sanofi Drug Profiles - cabazitaxel - efatutazone - everolimus - palbociclib - pembrolizumab - ribociclib - SAR-405838 - selinexor - trabectedin - Liposarcoma For more information visit http://www.researchandmarkets.com/research/sc...iposarcoma
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 388.23 (-11.06), ACOR: 34.07 (+0.65), GSK: 42.45 (+0.65), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.58 (-0.02), GALE: 1.63 (+0.10), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20)
Idiopathic (Essential) Hypertension Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ftwwp9/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Eli Lilly and Company - Jiangsu Hengrui Medicine Co., Ltd. - Lee's Pharmaceutical Holdings Limited - PhaseBio Pharmaceuticals, Inc. - Quantum Genomics SA - Takeda Pharmaceutical Company Limited Drug Profiles - (amlodipine besylate azilsartan medoxomil hydrochlorothiazide) - (amlodipine besylate candesartan) - (nifedipine candesartan cilexetil) - azilsartan medoxomil - carvedilol phosphate ER - - carvedilol SR - CS-3150 - LY-2623091 - PB-1120 - QGC-001 - rostafuroxin For more information visit http://www.researchandmarkets.com/research/ftwwp9/idiopathic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 88.29 (+0.81)
Pulmonary Embolism Pipeline Review 2015 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Mon Apr 27, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f85q3d/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - F. Hoffmann-La Roche Ltd. Drug Profiles - apixaban - edoxaban tosylate - rivaroxaban - Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - SMTP-7 - TRX-1 For more information visit http://www.researchandmarkets.com/research/f85q3d/pulmonary
BMY: 69.27 (+1.38)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 1.94 (-0.19), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CBPO: 111.03 (+7.77), DERM: 18.22 (+0.30), CCXI: 8.60 (+0.19), ANAC: 84.61 (+1.95), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14)
Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
PR Newswire Europe - Fri Apr 24, 6:56AM CDT
TOKYO, April 24, 2015 /PRNewswire/ --
Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 2:30PM CDT
The report "Pulmonary Embolism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pulmonary Embolism. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pulmonary-em...eport.html .
BMY: 69.27 (+1.38)
